大うつ病性障害（MDD）の治療における323U66 SRの固定用量試験

基本情報

NCT ID

NCT01138007

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

572

治験依頼者名

GlaxoSmithKline

概要

This is a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study to confirm the efficacy of 323U66 Sustained Release (SR) orally administered to patients with MDD (Major Depressive Disorder) at doses level of 150 mg/day and 300 mg/day for 8 weeks based on the decrease in MADRS (Montgomery-Asberg Depression Rating Scale) total score, and to evaluate the safety based on adverse events, clinical laboratory tests and vital signs.

対象疾患

介入

依頼者（Sponsor）